» Articles » PMID: 37539765

COVID-19 Vaccination in Patients With Cancer and Patients Receiving HSCT or CAR-T Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future

Overview
Journal J Infect Dis
Date 2023 Aug 4
PMID 37539765
Authors
Affiliations
Soon will be listed here.
Abstract

Patients with cancer demonstrate an increased vulnerability for infection and severe disease by SARS-CoV-2, the causative agent of COVID-19. Risk factors for severe COVID-19 include comorbidities, uncontrolled disease, and current line of treatment. Although COVID-19 vaccines have afforded some level of protection against infection and severe disease among patients with solid tumors and hematologic malignancies, decreased immunogenicity and real-world effectiveness have been observed among this population compared with healthy individuals. Characterizing and understanding the immune response to increasing doses or differing schedules of COVID-19 vaccines among patients with cancer is important to inform clinical and public health practices. In this article, we review SARS-CoV-2 susceptibility and immune responses to COVID-19 vaccination in patients with solid tumors, hematologic malignancies, and those receiving hematopoietic stem cell transplant or chimeric-antigen receptor T-cell therapy.

Citing Articles

Combined autologous hematopoietic stem cell transplantation and CD19 CAR T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma with mutation: A case report.

Cai Z, Zou D, Ma Q, Sun W, Guo Y SAGE Open Med Case Rep. 2025; 13:2050313X241306236.

PMID: 40078172 PMC: 11898238. DOI: 10.1177/2050313X241306236.


Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a two-year follow-up of the prospective clinical trial COVAXID.

Chen P, Bergman P, Blennow O, Hansson L, Mielke S, Nowak P EBioMedicine. 2024; 109:105385.

PMID: 39395230 PMC: 11663764. DOI: 10.1016/j.ebiom.2024.105385.


Effectiveness of Paxlovid in the treatment of the SARS-CoV-2 Omicron variant infection in children with hematologic malignancies: a retrospective cohort study.

Deng X, Jiang Y, Chen W, Qin X, Chen J, Li H Transl Cancer Res. 2024; 13(8):4219-4230.

PMID: 39262461 PMC: 11384919. DOI: 10.21037/tcr-24-70.


Mannan-Decorated Lipid Calcium Phosphate Nanoparticle Vaccine Increased the Antitumor Immune Response by Modulating the Tumor Microenvironment.

Wu L, Yang L, Qian X, Hu W, Wang S, Yan J J Funct Biomater. 2024; 15(8).

PMID: 39194667 PMC: 11355305. DOI: 10.3390/jfb15080229.


COVID-19 vaccine updates for people under different conditions.

Huang Y, Wang W, Liu Y, Wang Z, Cao B Sci China Life Sci. 2024; 67(11):2323-2343.

PMID: 39083202 DOI: 10.1007/s11427-024-2643-1.


References
1.
Yang W, Zhang D, Li Z, Zhang K . Predictors of poor serologic response to COVID-19 vaccine in patients with cancer: a systematic review and meta-analysis. Eur J Cancer. 2022; 172:41-50. PMC: 9160160. DOI: 10.1016/j.ejca.2022.05.031. View

2.
Hall V, Ferreira V, Wood H, Ierullo M, Majchrzak-Kita B, Manguiat K . Delayed-interval BNT162b2 mRNA COVID-19 vaccination enhances humoral immunity and induces robust T cell responses. Nat Immunol. 2022; 23(3):380-385. DOI: 10.1038/s41590-021-01126-6. View

3.
Lee L, Cazier J, Angelis V, Arnold R, Bisht V, Campton N . COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020; 395(10241):1919-1926. PMC: 7255715. DOI: 10.1016/S0140-6736(20)31173-9. View

4.
Abid M, Rubin M, Ledeboer N, Szabo A, Longo W, Mohan M . Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients. Cancer Cell. 2022; 40(4):340-342. PMC: 8864440. DOI: 10.1016/j.ccell.2022.02.010. View

5.
Fendler A, Au L, Shepherd S, Byrne F, Cerrone M, Boos L . Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. Nat Cancer. 2022; 2(12):1321-1337. DOI: 10.1038/s43018-021-00275-9. View